- Home
- VANI vs EPIX Comparison
VANI vs EPIX Comparison
Compare VANI & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- EPIX
- Stock Information
- Founded
- VANI 1998
- EPIX 2009
- Country
- VANI United States
- EPIX Canada
- Employees
- VANI 36
- EPIX N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- EPIX Health Care
- Exchange
- VANI Nasdaq
- EPIX Nasdaq
- Market Cap
- VANI 75.2M
- EPIX 75.9M
- IPO Year
- VANI 2014
- EPIX N/A
- Fundamental
- Price
- VANI $1.40
- EPIX $1.72
- Analyst Decision
- VANI Strong Buy
- EPIX Hold
- Analyst Count
- VANI 1
- EPIX 3
- Target Price
- VANI $4.00
- EPIX $2.00
- AVG Volume (30 Days)
- VANI 134.3K
- EPIX 53.1K
- Earning Date
- VANI 08-12-2025
- EPIX 08-04-2025
- Dividend Yield
- VANI N/A
- EPIX N/A
- EPS Growth
- VANI N/A
- EPIX N/A
- EPS
- VANI N/A
- EPIX N/A
- Revenue
- VANI N/A
- EPIX N/A
- Revenue This Year
- VANI N/A
- EPIX N/A
- Revenue Next Year
- VANI N/A
- EPIX N/A
- P/E Ratio
- VANI N/A
- EPIX N/A
- Revenue Growth
- VANI N/A
- EPIX N/A
- 52 Week Low
- VANI $0.91
- EPIX $1.40
- 52 Week High
- VANI $1.50
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- VANI 74.26
- EPIX 51.31
- Support Level
- VANI $1.26
- EPIX $1.68
- Resistance Level
- VANI $1.30
- EPIX $1.75
- Average True Range (ATR)
- VANI 0.06
- EPIX 0.04
- MACD
- VANI 0.00
- EPIX 0.00
- Stochastic Oscillator
- VANI 69.70
- EPIX 62.50
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.